Pharnext Announces Issuance of New Composition of Matter Patents Covering First-in-Class PLEODRUGTM PXT3003 and PXT864
• Expands foundational patent protection for Pharnext’s innovative drug combinations as new products
• Two first-in-class PLEODRUG products were developed using Pharnext’s R&D platform, PLEOTHERAPYTM
PARIS, France, 7:30 am, July 18 2018 (CEST) – Pharnext SA (FR0011191287 – ALPHA) a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, today announced the issuance of composition of matter patents, securing protection as new entities, for two PLEODRUGTM products, PXT3003 and PXT864.